Idiopathic Pulmonary Fibrosis

Goal of Program:

Idiopathic pulmonary fibrosis is a specific form of interstitial lung disease that occurs almost exclusively in older individuals and has no proven effective therapies. Our program employs a multidisciplinary approach to the diagnosis and treatment of IPF with the primary objective being to provide state-of-the-art care that improves the quality of life for patients with this condition.

Who We Are:

  • Sandra Weibel, MD, Assistant Professor of Medicine, specializes in treatment of interstitial lung disease and has been a leader in treatment of scleroderma lung disease at Thomas Jefferson University for over 15 years.
  • Ross Summer, MD, Associate Professor of Medicine, physician-scientist who specializes in treatment of interstitial lung disease and engages in laboratory investigation to better understand the molecular mechanisms driving the development of lung fibrosis.
  • Michael Scharf, MD. Associate Professor of Medicine, specializes in treatment of pulmonary hypertension and has extensive experience with treatment scleroderma-related PAH.
  • Jennifer Sloan, MD - Assistant Professor of Medicine, Department of Rheumatology, specializes in treatment of extra-pulmonary manifestations of connective tissue associated lung disease.

Clinical Activities:

  • Evaluation of potential inciting factors, such as medications, collagen vascular disease, occupational or other inhalational exposures
  • Pulmonary function testing
  • High resolution lung CT scan
  • Flexible fiberoptic bronchoscopy or video assisted lung biopsy
  • Review of all of these studies to determine the type of interstitial lung disease
  • Use of immunosuppressive or immunomodulatory therapy
  • Innovative therapies for refractory disease
  • Referral for lung transplant evaluation
  • Referral for pulmonary rehabilitation
  • Provide counseling

Clinical trials:

Idiopathic pulmonary fibrosis/Usual interstitial pneumonitis remains a disease of unknown etiology and without proven effective therapy. Our focus is to develop an understanding of the causes and pathogenesis at both the basic science and clinical levels in order to develop more disease- and patient-specific treatments. Until effective therapies are discovered, we encourage patients to participate in clinical trials so that we can one day improve the lives for patients with this condition. We are currently enrolling patients with idiopathic pulmonary fibrosis in the GS-US-322-0207 study trial, a global study of a novel humanized monoclonal antibody that binds to LOXL2. This therapy aims to reduce morbidity and mortality from this serious condition. If you wish to discuss research going on at our institution, we welcome the opportunity. Please contact Dr. Ross Summer at for more information on this study.


For Patients:

How to Schedule an appointment

Call 1 800-JEFFNOW and ask the operator to schedule a new patient visit with Dr. Summer or Dr. Weibel for an evaluation of ”interstitial lung disease”.  Alternatively, one can either call our pulmonary offices directly by dialing (215) 955-5161, option 2 or by e-mailing one of our physicians at or

How to Get Here